About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The broad purpose of the Epidemiology and Public Health research group is contributing to increase the available scientific evidence regarding preventive interventions, to promote health, and prevent morbidity and mortality from major diseases. Our group uses epidemiological methods to study etiology, surveillance, and efficacy of these interventions. We are primarily focused on epidemiology and prevention of infectious diseases, in both individual and population levels. Main lines of research:
PMID: 34844263 Journal: Blood Advances Year: 2022 Reference: Blood Adv. 2022 Feb 8;6(3):774-784. doi: 10.1182/bloodadvances.2021006101. Impact factor: Publication type: Paper in international publication Authors: Abrisqueta, Pau; Barba, Pere; Bosch, Francesc; Cabirta, Alba; Campins, Magda; Catala, Eva; Crespo, Marta; Esperalba, Juliana; Fernandez-Naval, Candela; Fox, Maria Laura et al. DOI: 10.1182/bloodadvances.2021006101
PMID: 32856989 Journal: Multiple Sclerosis Journal Year: 2022 Reference: Mult Scler. 2022 Feb;28(2):173-182. doi: 10.1177/1352458520952022. Epub 2020 Aug 28. Impact factor: Publication type: Paper in international publication Authors: Baro, Francesc; Midaglia, Luciana; Montalban, Xavier; Otero, Susana; Tintore, Mar et al. DOI: 10.1177/1352458520952022
PMID: 35039796 Journal: BMJ open ophthalmology Year: 2022 Reference: BMJ Open Ophthalmol. 2022 Jan 11;7(1):e000867. doi: 10.1136/bmjophth-2021-000867. eCollection 2022. Impact factor: Publication type: Paper in international publication Authors: Aragon, David; Azarfane, Brahim; Banderas Garcia, Sandra; Garcia-Arumi, Jose; Garrell-Salat, Xavier; Otero-Romero, Susana; Sanchez-Montalva, Adrian; Trejo, Fernando; Zapata, Miguel Angel et al. DOI: 10.1136/bmjophth-2021-000867
PMID: 35001198 Journal: JOURNAL OF NEUROLOGY Year: 2022 Reference: J Neurol. 2022 Apr;269(4):1764-1772. doi: 10.1007/s00415-021-10958-z. Epub 2022 Jan 10. Impact factor: Publication type: Paper in international publication Authors: Arrambide, Georgina; Auger, Cristina; Carbonell, Pere; Cardenas-Robledo, Simon; Castillo, Joaquin; Castillo, Mireia; Cobo-Calvo, Alvaro; Comabella, Manuel; Espejo, Carmen; Galan, Ingrid et al. DOI: 10.1007/s00415-021-10958-z
PMID: 34384612 Journal: MEDICINA CLINICA Year: 2021 Reference: Med Clin (Barc). 2021 Jul 26. pii: S0025-7753(21)00433-4. doi: 10.1016/j.medcli.2021.07.005. Impact factor: 1.725 Publication type: Letter whit IF Authors: Escola-Verge, Laura, Borras-Bermejo, Blanca, Los-Arcos, Ibai, Esperalba, Juliana, Ferrer, Carmen, Fernandez-Hidalgo, Nuria et al. DOI: 10.1016/j.medcli.2021.07.005
PMID: 34018483 Journal: Eurosurveillance Year: 2021 Reference: Euro Surveill. 2021 May;26(20). doi: 10.2807/1560-7917.ES.2021.26.20.2001138. Impact factor: 6.307 Publication type: Paper in international publication Authors: Martin-Sanchez, Mario, Mercuriali, Lilas, Borras-Bermejo, Blanca, Lopez-Contreras, Joaquin, Vilella, Anna, Villar, Judit, Orcau, Angels, de Olalla, Patricia Garcia, Rius, Cristina, de Andres, Anna et al. DOI: 10.2807/1560-7917.ES.2021.26.20.2001138
PMID: 33761874 Journal: BMC Family Practice Year: 2021 Reference: BMC Fam Pract. 2021 Mar 25;22(1):56. doi: 10.1186/s12875-021-01414-y. Impact factor: 2.497 Publication type: Paper in international publication Authors: Coma, Ermengol, Mora, Nuria, Peremiquel-Trillas, Paula, Benitez, Mencia, Mendez, Leonardo, Mercade, Albert, Fina, Francesc, Fabregas, Mireia, Medina, Manuel et al. DOI: 10.1186/s12875-021-01414-y
PMID: 32229130 Journal: ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA Year: 2021 Reference: Enferm Infecc Microbiol Clin. 2021 Mar;39(3):134-138. doi: 10.1016/j.eimc.2020.02.015. Epub 2020 Mar 27. Impact factor: 1.731 Publication type: Paper in national publication Authors: Melendo, Susana, Fernandez-Polo, Aurora, Castellnou Asens, Ivette, Mendoza-Palomar, Natalia, Barnes-Mayolas, Meritxell, Soler-Palacin, Pere, Soler Palacin, Pere, Melendo Perez, Susana, Mendoza Palomar, Natalia, Nieves Larrosa Escartin, M et al. DOI: 10.1016/j.eimc.2020.02.015
On European Antibiotic Awareness Day, we highlight the importance of using these medications responsibly and finding innovative solutions to combat this issue.
This strategy protects almost two thirds of patients. It also reduces the waiting time between vaccination and initiation of immune suppressive treatment.
El VHIR va participar activament en l'assaig clínic d'aquesta vacuna que avaluava la seguretat, la tolerabilitat i l'eficàcia.
